您的购物车当前为空
别名 SCYE1, p43, HLD3, EMAP-II, EMAP-2, AIMP1
The potent antiangiogenic and proinflammatory protein Endothelial Monocyte Activating Polypeptide II (EMAP II) has been described as a mediator of pulmonary vascular and alveolar formation and its expression is inversely related to the periods of vascularization and alveolarization in the developing lung. Hence the study of EMAP II could play a vital role in studying and devising appropriate therapeutics for diseases of aberrant lung development, such as BPD.

The potent antiangiogenic and proinflammatory protein Endothelial Monocyte Activating Polypeptide II (EMAP II) has been described as a mediator of pulmonary vascular and alveolar formation and its expression is inversely related to the periods of vascularization and alveolarization in the developing lung. Hence the study of EMAP II could play a vital role in studying and devising appropriate therapeutics for diseases of aberrant lung development, such as BPD.
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 5 μg | ¥ 283 | 6-8日内发货 | |
| 10 μg | ¥ 446 | 6-8日内发货 | |
| 20 μg | ¥ 723 | 5日内发货 | |
| 50 μg | ¥ 1,380 | 5日内发货 | |
| 100 μg | ¥ 2,360 | 5日内发货 | |
| 200 μg | ¥ 4,280 | 5日内发货 | |
| 500 μg | ¥ 9,490 | 5日内发货 |
| 产品描述 | The potent antiangiogenic and proinflammatory protein Endothelial Monocyte Activating Polypeptide II (EMAP II) has been described as a mediator of pulmonary vascular and alveolar formation and its expression is inversely related to the periods of vascularization and alveolarization in the developing lung. Hence the study of EMAP II could play a vital role in studying and devising appropriate therapeutics for diseases of aberrant lung development, such as BPD. |
| 生物活性 | Activity has not been tested. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first. |
| 研究背景 | The potent antiangiogenic and proinflammatory protein Endothelial Monocyte Activating Polypeptide II (EMAP II) has been described as a mediator of pulmonary vascular and alveolar formation and its expression is inversely related to the periods of vascularization and alveolarization in the developing lung. Hence the study of EMAP II could play a vital role in studying and devising appropriate therapeutics for diseases of aberrant lung development, such as BPD. |
| 种属 | Mouse |
| 表达系统 | E. coli |
| 标签 | N-His |
| 蛋白编号 | P31230 |
| 蛋白构建 | Ala2-Lys310 |
| 蛋白纯度 | > 95% as determined by Tris-Bis PAGE |
| 蛋白性状 | Solution |
| 缓冲液 | Supplied as 0.22 μm filtered solution in 20 mM Tris, 500 mM NaCl, 10% Glycerol (pH 8.0). |
| 别名 | SCYE1, p43, HLD3, EMAP-II, EMAP-2, AIMP1 |
| 内毒素 | < 1 EU/μg by the LAL method. |
| 分子量 | 35.1 kDa (predicted). The protein migrates to 42-46 kDa based on Tris-Bis PAGE result. |
| 运输方式 | In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice. |
| 存储 | It is recommended to store the product under sterile conditions at -70°C or lower. Samples are stable for up to 12 months at -80°C. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
对于不同动物的给药剂量换算,您也可以参考 更多